{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T10:29:23Z","timestamp":1777544963561,"version":"3.51.4"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"TEPHINET\/APDC (Abbott Pandemic Defense Coalition) Field Epidemiology Training Program Fellowship"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Hepatitis C virus (HCV) infection is associated with hepatocellular carcinoma (HCC), the predominant form of primary liver cancer (PLC). In 2015, Georgia implemented the HCV Elimination Program to reduce high national prevalence. We analyzed linked national registry data to characterize primary liver cancer cases in Georgia and evaluate the burden and treatment patterns of HCV infection among affected individuals during the national HCV elimination program. Data from the Georgian Cancer Registry (GCR), the national Vital Registration System, and the HCV Elimination Program databases were linked to perform a descriptive analysis of adult PLC cases diagnosed between January 2015-December 2022 and examine trends in HCV infection and treatment among them. Of 1734 reported PLC cases, 72.0% were male with a median age of 63 years (IQR 56\u201370). Two-thirds presented with stage 3\u20134 liver cancer and 80.2% were deceased by the end of 2022. Screening for HCV among PLC cases rose from 14.0% in 2015 to 92.8% in 2022. Of 1389 tested, 785 (56.5%) were anti-HCV positive. Of these, 654 (83.3%) were confirmed to be HCV RNA or HCVcAg positive, 472 (72.2%) of which had advanced liver fibrosis or cirrhosis. Among 654 HCV RNA or HCVcAg positive individuals, 495 (75.7%) initiated HCV treatment, with 355 (71.7%) treated more than one year before their PLC diagnosis. Our analysis supports the known association between PLC and HCV infection in Georgia. The high proportion of PLC cases receiving HCV treatment prior to their liver cancer diagnosis highlights the need to establish routine post-treatment follow-up for cirrhotic patients to facilitate earlier detection of PLC and improve outcomes.<\/jats:p>","DOI":"10.1371\/journal.pone.0347697","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:31:52Z","timestamp":1777397512000},"page":"e0347697","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Primary liver cancer in Georgia: Seven years\u2019 experience following the launch of the Hepatitis C Elimination Program, 2015\u20132022"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2460-7105","authenticated-orcid":true,"given":"Anna","family":"Khoperia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan H.","family":"Gawel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna","family":"Bedrava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazibrola","family":"Chitadze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maia","family":"Butsashvili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Landay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoff A.","family":"Beckett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Surguladze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantine","family":"Kazanjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9337-1908","authenticated-orcid":true,"given":"Vladimer","family":"Getia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maia","family":"Tsereteli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maia","family":"Alkhazashvili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gavin A.","family":"Cloherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamuka","family":"Zakalashvili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amiran","family":"Gamkrelidze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Averhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"issue":"3","key":"pone.0347697.ref001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"pone.0347697.ref002","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"H Rumgay","year":"2022","journal-title":"Journal of Hepatology"},{"key":"pone.0347697.ref003","doi-asserted-by":"crossref","DOI":"10.54394\/CJQU6666","volume-title":"Global hepatitis report 2024: action for access in low- and middle-income countries","author":"World Health Organization","year":"2024"},{"issue":"9","key":"pone.0347697.ref004","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(16)30143-7","article-title":"Global burden of cancers attributable to infections in 2012: a synthetic analysis","volume":"4","author":"M Plummer","year":"2016","journal-title":"The Lancet Global Health"},{"issue":"6","key":"pone.0347697.ref005","article-title":"Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma","volume":"142","author":"HB El-Serag","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"pone.0347697.ref006","first-page":"79","article-title":"Hepatitis C virus and hepatocellular carcinoma: a narrative review","volume":"6","author":"P Axley","year":"2018","journal-title":"J Clin Transl Hepatol"},{"issue":"12","key":"pone.0347697.ref007","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/ijc.31280","article-title":"Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide","volume":"142","author":"D Maucort\u2010Boulch","year":"2018","journal-title":"Intl Journal of Cancer"},{"key":"pone.0347697.ref008","author":"National Statistics Office of Georgia"},{"key":"pone.0347697.ref009","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-019-6784-3","article-title":"Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination","volume":"19","author":"LM Hagan","year":"2019","journal-title":"BMC Public Health"},{"issue":"28","key":"pone.0347697.ref010","doi-asserted-by":"crossref","first-page":"753","DOI":"10.15585\/mmwr.mm6428a2","article-title":"Launch of a nationwide hepatitis C elimination program\u2014Georgia, April 2015","volume":"64","author":"K Mitruka","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"pone.0347697.ref011","volume-title":"Strategic plan for the elimination of hepatitis C virus in Georgia, 2016\u20132020","author":"Georgia Ministry of Internally Displaced Persons from the Occupied Territories, Health, and Social Affairs","year":"2017"},{"issue":"4","key":"pone.0347697.ref012","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jhep.2019.06.026","article-title":"Excellence in viral hepatitis elimination\u2014lessons from Georgia","volume":"71","author":"F Averhoff","year":"2019","journal-title":"J Hepatol"},{"key":"pone.0347697.ref013","volume-title":"Hepatitis C elimination in Georgia brief","author":"National Center for Disease Control and Public Health","year":"2022"},{"issue":"6","key":"pone.0347697.ref014","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/infdis\/jiad064","article-title":"Nationwide Hepatitis C Serosurvey and Progress Towards Hepatitis C Virus Elimination in the Country of Georgia, 2021","volume":"228","author":"A Gamkrelidze","year":"2023","journal-title":"The Journal of Infectious Diseases"},{"issue":"1","key":"pone.0347697.ref015","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-024-09916-7","article-title":"Hepatitis C virus attributable liver cancer in the country of Georgia, 2015\u20132019: a case\u2013control study","volume":"24","author":"S Surguladze","year":"2024","journal-title":"BMC Infect Dis"},{"key":"pone.0347697.ref016","volume-title":"Medical statistics: Georgia brief 2020","author":"National Center for Disease Control and Public Health"},{"key":"pone.0347697.ref017","volume-title":"International classification of diseases tenth revision (ICD-10), sixth edition","author":"World Health Organization","year":"2019"},{"issue":"29","key":"pone.0347697.ref018","doi-asserted-by":"crossref","first-page":"773","DOI":"10.15585\/mmwr.mm6629a2","article-title":"The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination \u2014 Georgia, 2015\u20132016","volume":"66","author":"M Nasrullah","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"pone.0347697.ref019","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection: comparison with liver biopsy and fibrotest","volume":"46","author":"A Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"issue":"11","key":"pone.0347697.ref020","article-title":"Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community","volume":"13","author":"P-N Cheng","year":"2018","journal-title":"PLoS ONE"},{"issue":"1","key":"pone.0347697.ref021","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","author":"European Association for the Study of the Liver, Asociaci\u00f3n Latinoamericana para el Estudio del H\u00edgado","year":"2015","journal-title":"J Hepatol"},{"key":"pone.0347697.ref022","unstructured":"Aslanikashvili A. HCV-attributable hepatocellular carcinoma among persons with hepatobiliary cancer diagnoses in Georgia: 2015\u20132016. In: Tbilisi, Georgia, 2018."},{"issue":"1","key":"pone.0347697.ref023","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long\u2010Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents","volume":"71","author":"F Kanwal","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"pone.0347697.ref024","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"68","author":"GN Ioannou","year":"2018","journal-title":"J Hepatol"},{"key":"pone.0347697.ref025","volume-title":"National hepatitis C virus elimination progress report Georgia, 2015\u20132017","author":"Georgia Ministry of Health, Labour and Social Affairs","year":"2019"},{"issue":"4","key":"pone.0347697.ref026","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jhep.2019.11.019","article-title":"Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia","volume":"72","author":"F Averhoff","year":"2020","journal-title":"J Hepatol"},{"key":"pone.0347697.ref027","doi-asserted-by":"crossref","first-page":"106153","DOI":"10.1016\/j.ypmed.2020.106153","article-title":"Screening and linkage to care for hepatitis C among inpatients in Georgia\u2019s national hospital screening program","volume":"138","author":"S Shadaker","year":"2020","journal-title":"Prev Med"},{"issue":"10","key":"pone.0347697.ref028","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"JD Yang","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"30","key":"pone.0347697.ref029","doi-asserted-by":"crossref","first-page":"2200837","DOI":"10.2807\/1560-7917.ES.2023.28.30.2200837","article-title":"Toward reaching hepatitis B goals: hepatitis B epidemiology and the impact of two decades of vaccination, Georgia, 2021","volume":"28","author":"N Khetsuriani","year":"2023","journal-title":"Euro Surveill"},{"key":"pone.0347697.ref030","volume-title":"2020 country progress report \u2013 Georgia global AIDS monitoring","author":"Joint United Nations Programme on HIV\/AIDS UNAIDS"},{"key":"pone.0347697.ref031","volume-title":"HIV-related risk behaviors and HIV prevalence among men who have sex with men and population size estimation report","author":"Health Research Union","year":"2023"},{"issue":"3","key":"pone.0347697.ref032","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"74","author":"LA Krassenburg","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"pone.0347697.ref033","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.29126","article-title":"Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma","volume":"66","author":"B Saberi","year":"2017","journal-title":"Hepatology"},{"key":"pone.0347697.ref034","doi-asserted-by":"crossref","DOI":"10.20517\/2394-5079.2019.15","article-title":"Management of concomitant hepatocellular carcinoma and chronic hepatitis C: a review","volume":"2019","author":"E Harrod","year":"2019","journal-title":"HR"},{"issue":"1","key":"pone.0347697.ref035","first-page":"1","article-title":"Direct-acting antiviral treatment for patients with hepatocellular carcinoma","volume":"34","author":"T Kushner","year":"2018","journal-title":"Curr Opin Gastroenterol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0347697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:32:02Z","timestamp":1777397522000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0347697"}},"subtitle":[],"editor":[{"given":"Jason T.","family":"Blackard","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0347697","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]}}}